IceCure Medical (NASDAQ:ICCM – Get Free Report) and Biotricity (NASDAQ:BTCY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.
Insider & Institutional Ownership
0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares IceCure Medical and Biotricity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -376.85% | -124.44% | -87.70% |
| Biotricity | -80.42% | N/A | -188.47% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.29 million | 20.24 | -$14.65 million | ($0.30) | -4.00 |
| Biotricity | $12.06 million | 0.95 | -$14.09 million | ($1.08) | -0.43 |
Biotricity has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for IceCure Medical and Biotricity, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 0 | 0 | 1 | 1 | 3.50 |
| Biotricity | 0 | 1 | 0 | 0 | 2.00 |
IceCure Medical presently has a consensus target price of $2.50, suggesting a potential upside of 108.33%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Biotricity.
Volatility and Risk
IceCure Medical has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Summary
Biotricity beats IceCure Medical on 8 of the 15 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
